Showing 1 - 5 results of 5 for search '"Therapeutic Goods Administration"', query time: 0.04s Refine Results
  1. 1

    Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review by Kiran Shah, Nirali Shah, Fatameh Ghassemi, Carolyn Ly, Teena George, Carla Lutz, Huseyin Sumer

    Published 2022-01-01
    “…The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA’s Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. …”
    Get full text
    Article
  2. 2

    Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease by Ryan Jalleh, Gopal Basu, Richard Le Leu, Shilpanjali Jesudason

    Published 2018-01-01
    “…Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia, raising concern about lack of widespread awareness among prescribing practitioners. …”
    Get full text
    Article
  3. 3

    The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease by Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke, Ieuan E S Evans

    Published 2025-12-01
    “…Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor. …”
    Get full text
    Article
  4. 4

    Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: seconda... by Helen Macpherson, Robin M Daly, Patricia M Livingston, Declan G Murphy, Patrick J Owen, Timo Rantalainen, Niamh L Mundell, Jeremy L Millar, Steve F Fraser, Jack Dalla Via, Stephen J Foulkes

    Published 2022-06-01
    “…Exercise training adherence below recommended guidelines does not support cognitive health in men treated with ADT for prostate cancer.Trial registration number Australian and New Zealand Clinical Trial Registry (ACTRN12614000317695, registered 25/03/2014) and acknowledged under the Therapeutic Goods Administration Clinical Trial Notification Scheme (CT-2015-CTN-03372-1 v1).…”
    Get full text
    Article
  5. 5